Ascelia Pharma AB (publ) (ACE.ST) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-09-08). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. ACE.ST files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.17% | 30.00% | Pass |
| Interest-bearing investments | 60.28% | 30.00% | Fail |
ℹ️ Dow Jones Islamic Market, MSCI M-Series, S&P Shariah divide by a trailing-average market cap (24- or 36-month) rather than today's. That price history is not collected for non-US listings, so these are reported as unverified — it reflects a missing input on our side, not anything about the company.
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 44.20 | NEUTRAL |
| Stochastic %K (14) | 80.61 | SELL |
| CCI (20) | 92.71 | NEUTRAL |
| Williams %R (14) | -19.39 | SELL |
| MACD (12,26,9) | 0.03 | BUY |
| ROC (10) | 2.24 | BUY |
| Momentum (10) | 0.01 | BUY |
| EMA (10) | 0.63 | BUY |
| SMA (10) | 0.63 | BUY |
| EMA (20) | 0.63 | BUY |
| SMA (20) | 0.61 | BUY |
| EMA (30) | 0.70 | SELL |
| SMA (30) | 0.60 | BUY |
| EMA (50) | 0.93 | SELL |
| SMA (50) | 0.64 | BUY |
| EMA (100) | 1.50 | SELL |
| SMA (100) | 1.82 | SELL |
| EMA (200) | 2.09 | SELL |
| SMA (200) | 2.40 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
